Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Parkinson's Disease

  Free Subscription


28.01.2019

1 Int J Neurosci
1 J Neurol Neurosurg Psychiatry
2 Lancet Neurol
11 Mov Disord
2 N Engl J Med
1 Nat Rev Neurol
1 Neuron
1 Neuropsychology
1 Neuroscience
1 PLoS One
1 Proc Natl Acad Sci U S A
1 Rev Neurol (Paris)


   Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Int J Neurosci

  1. WANG Y, Zhou Y, Wang X, Zhen F, et al
    Osthole alleviates MPTP-induced parkinson's disease mice by suppressing Notch signaling pathway.
    Int J Neurosci. 2019 Jan 22:1-11. doi: 10.1080/00207454.2019.1573171.
    PubMed     Text format     Abstract available


    J Neurol Neurosurg Psychiatry

  2. SHEPARD MD, Perepezko K, Broen MPG, Hinkle JT, et al
    Suicide in Parkinson's disease.
    J Neurol Neurosurg Psychiatry. 2019 Jan 19. pii: jnnp-2018-319815.
    PubMed     Text format     Abstract available


    Lancet Neurol

  3. RASCOL O
    CVT-301 for Parkinson's disease: dose and effect size issues.
    Lancet Neurol. 2019;18:128-130.
    PubMed     Text format    

  4. LEWITT PA, Hauser RA, Pahwa R, Isaacson SH, et al
    Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet Neurol. 2019;18:145-154.
    PubMed     Text format     Abstract available


    Mov Disord

  5. WARREN OLANOW C, Torti M, Kieburtz K, Leinonen M, et al
    Continuous versus intermittent oral administration of levodopa in Parkinson's disease patients with motor fluctuations: A pharmacokinetics, safety, and efficacy study.
    Mov Disord. 2019 Jan 17. doi: 10.1002/mds.27610.
    PubMed     Text format     Abstract available

  6. SEPPI K, Ray Chaudhuri K, Coelho M, Fox SH, et al
    Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review.
    Mov Disord. 2019 Jan 17. doi: 10.1002/mds.27602.
    PubMed     Text format     Abstract available

  7. HOOGLAND J, Boel JA, de Bie RMA, Schmand BA, et al
    Risk of Parkinson's disease dementia related to level I MDS PD-MCI.
    Mov Disord. 2019 Jan 17. doi: 10.1002/mds.27617.
    PubMed     Text format     Abstract available

  8. VOGELNIK K, Kojovic M
    From beta-blockers to Parkinson's disease in respect of essential tremor.
    Mov Disord. 2019;34:153.
    PubMed     Text format    


  9. Retraction: 'Abnormal bone and calcium metabolism in immobilized Parkinson's disease patients,' by Sato Y., Honda Y., Iwamoto, J., Kanoko, T., and Satoh, K.
    Mov Disord. 2019;34:156.
    PubMed     Text format    

  10. GRONICH N, Auriel E, Lavi I, Rennert G, et al
    Reply to: From beta-blockers to Parkinson's disease in respect of essential tremor.
    Mov Disord. 2019;34:154.
    PubMed     Text format    

  11. ASCHERIO A, Schwarzschild MA
    Lifestyle and Parkinson's disease progression.
    Mov Disord. 2019;34:7-8.
    PubMed     Text format    

  12. PAUL KC, Chuang YH, Shih IF, Keener A, et al
    The association between lifestyle factors and Parkinson's disease progression and mortality.
    Mov Disord. 2019;34:58-66.
    PubMed     Text format     Abstract available

  13. MARRAS C, Obeso JA
    We are what we eat - editors' note on the role of diet in Parkinson's disease.
    Mov Disord. 2019;34:1.
    PubMed     Text format    

  14. BANDRES-CIGA S, Saez-Atienzar S, Bonet-Ponce L, Billingsley K, et al
    The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease.
    Mov Disord. 2019 Jan 24. doi: 10.1002/mds.27614.
    PubMed     Text format     Abstract available

  15. BLESA J, Vila M
    Parkinson disease, substantia nigra vulnerability, and calbindin expression: Enlightening the darkness?
    Mov Disord. 2019 Jan 24. doi: 10.1002/mds.27618.
    PubMed     Text format    


    N Engl J Med

  16. VERSCHUUR CVM, Suwijn SR, Boel JA, Post B, et al
    Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease.
    N Engl J Med. 2019;380:315-324.
    PubMed     Text format     Abstract available

  17. BRESSMAN S, Saunders-Pullman R
    When to Start Levodopa Therapy for Parkinson's Disease.
    N Engl J Med. 2019;380:389-390.
    PubMed     Text format    


    Nat Rev Neurol

  18. DEUSCHL G, de Bie RMA
    New therapeutic developments for Parkinson disease.
    Nat Rev Neurol. 2019 Jan 16. pii: 10.1038/s41582-019-0133.
    PubMed     Text format    


    Neuron

  19. TANIMURA A, Du Y, Kondapalli J, Wokosin DL, et al
    Cholinergic Interneurons Amplify Thalamostriatal Excitation of Striatal Indirect Pathway Neurons in Parkinson's Disease Models.
    Neuron. 2019 Jan 4. pii: S0896-6273(18)31080.
    PubMed     Text format     Abstract available


    Neuropsychology

  20. BAERTSCHI M, Flores Alves Dos Santos J, Burkhard P, Weber K, et al
    The burden of normality as a model of psychosocial adjustment after deep brain stimulation for Parkinson's disease: A systematic investigation.
    Neuropsychology. 2019 Jan 21. pii: 2019-01999-001. doi: 10.1037/neu0000509.
    PubMed     Text format     Abstract available


    Neuroscience

  21. RAHMAN AA, Morrison BE
    Contributions of VPS35 Mutations to Parkinson's Disease.
    Neuroscience. 2019 Jan 18. pii: S0306-4522(19)30017.
    PubMed     Text format     Abstract available


    PLoS One

  22. TESSA C, Toschi N, Orsolini S, Valenza G, et al
    Central modulation of parasympathetic outflow is impaired in de novo Parkinson's disease patients.
    PLoS One. 2019;14:e0210324.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  23. LEVINE PM, Galesic A, Balana AT, Mahul-Mellier AL, et al
    alpha-Synuclein O-GlcNAcylation alters aggregation and toxicity, revealing certain residues as potential inhibitors of Parkinson's disease.
    Proc Natl Acad Sci U S A. 2019 Jan 16. pii: 1808845116.
    PubMed     Text format     Abstract available


    Rev Neurol (Paris)

  24. WITJAS-SLUCKI T
    Surgical treatments for tremors.
    Rev Neurol (Paris). 2018;174:615-620.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: